GSK files multiple myeloma drug with FDA after phase 2 succe...

GSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple myeloma on the basis of a set of strong results fr

J&J gets okay for a third first-line Darzalex combo in US

GSK scores major trial win with potential multiple myeloma b...

GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma.

GSK hires former Genentech expert for AI unit

FDA reviews Sanofi's multiple myeloma drug isatuximab

The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.

FDA clears Karyopharm’s myeloma drug despite advisory panel ...